By Application
Hot products 
-
Mouse Anti-CRYAB Recombinant Antibody (A4345) (CBMAB-A4345-YC)
-
Mouse Anti-CD24 Recombinant Antibody (ALB9) (CBMAB-0176CQ)
-
Mouse Anti-ARID3A Antibody (A4) (CBMAB-0128-YC)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Mouse Anti-AKR1C3 Recombinant Antibody (V2-12560) (CBMAB-1050-CN)
-
Mouse Anti-ALB Recombinant Antibody (V2-363290) (CBMAB-S0173-CQ)
-
Mouse Anti-FN1 Monoclonal Antibody (71) (CBMAB-1241CQ)
-
Mouse Anti-AAV9 Recombinant Antibody (V2-634029) (CBMAB-AP023LY)
-
Mouse Anti-ADIPOR2 Recombinant Antibody (V2-179983) (CBMAB-A1369-YC)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
-
Mouse Anti-ENO1 Recombinant Antibody (CBYC-A950) (CBMAB-A4388-YC)
-
Mouse Anti-BRCA2 Recombinant Antibody (CBYY-0790) (CBMAB-0793-YY)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Mouse Anti-APOA1 Monoclonal Antibody (CBFYR0637) (CBMAB-R0637-FY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-C5B-9 Recombinant Antibody (CBFYA-0216) (CBMAB-X0304-FY)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
